A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines

Patrizia Vici, Luigi Di Lauro, Domenico Sergi, Paolo Foggi, Giuditta Viola, Marcella Mottolese, Francesco Giotta, Silvia I S Fattoruso, Serena Corsetti, Diana Giannarelli, Claudio Botti, Massimo Lopez

Research output: Contribution to journalArticle

Abstract

Background: It was the aim of this study to evaluate the efficacy of docetaxel and vinorelbine combination in well-defined anthracycline-'exposed' or -'resistant' advanced breast cancer patients. Patients and Methods: A phase II trial was carried out enrolling 43 advanced breast cancer patients, all previously treated with anthracyclines, both in an adjuvant or advanced setting. Docetaxel 75 mg/m2 as 1-hour infusion and vinorelbine 25 mg/m 2 as 30-min infusion were administered on day 1, every 3 weeks. Results: According to an intent-to-treat analysis, the response rate was 37.2% (95% CI 22.8-51.6) in 43 patients, whereas responses were observed in 16 (1 complete response, 15 partial response) out of 39 evaluable patients (41%, 95% CI 25.6-56.5); there were 50% with first-line and 33% with second-line therapy, and 50 and 29% of patients were considered anthracycline 'exposed' and 'resistant', respectively; responses by estrogen receptor (ER) status were given in 48% (ER positive) and 25% (ER negative), and by HER2 status, in 21% (HER2 positive) and 52% (HER2 negative). Median time to progression and median overall survival were 7.7 and 28.7 months, respectively. Toxicity was generally acceptable, with grade 3 neutropenia encountered in 15 (35%) patients and grade 4 neutropenia in 1 (2%) patient. Neutropenic fever occurred in 7 patients (16%), usually short-lasting. Grade 3 mucositis was encountered in 2 patients (5%). Conclusions: The combination of docetaxel and vinorelbine as a 3-weekly schedule is active and manageable in advanced breast cancer patients previously treated with anthracyclines.

Original languageEnglish
Pages (from-to)175-181
Number of pages7
JournalOncology
Volume75
Issue number3-4
DOIs
Publication statusPublished - Oct 2008

Fingerprint

docetaxel
Anthracyclines
Breast Neoplasms
Estrogen Receptors
Neutropenia
vinorelbine
Mucositis

Keywords

  • Advanced breast cancer
  • Chemotherapy
  • Docetaxel
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. / Vici, Patrizia; Di Lauro, Luigi; Sergi, Domenico; Foggi, Paolo; Viola, Giuditta; Mottolese, Marcella; Giotta, Francesco; Fattoruso, Silvia I S; Corsetti, Serena; Giannarelli, Diana; Botti, Claudio; Lopez, Massimo.

In: Oncology, Vol. 75, No. 3-4, 10.2008, p. 175-181.

Research output: Contribution to journalArticle

Vici, Patrizia ; Di Lauro, Luigi ; Sergi, Domenico ; Foggi, Paolo ; Viola, Giuditta ; Mottolese, Marcella ; Giotta, Francesco ; Fattoruso, Silvia I S ; Corsetti, Serena ; Giannarelli, Diana ; Botti, Claudio ; Lopez, Massimo. / A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines. In: Oncology. 2008 ; Vol. 75, No. 3-4. pp. 175-181.
@article{64b464d86aae4985b90a93e328d25b0b,
title = "A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines",
abstract = "Background: It was the aim of this study to evaluate the efficacy of docetaxel and vinorelbine combination in well-defined anthracycline-'exposed' or -'resistant' advanced breast cancer patients. Patients and Methods: A phase II trial was carried out enrolling 43 advanced breast cancer patients, all previously treated with anthracyclines, both in an adjuvant or advanced setting. Docetaxel 75 mg/m2 as 1-hour infusion and vinorelbine 25 mg/m 2 as 30-min infusion were administered on day 1, every 3 weeks. Results: According to an intent-to-treat analysis, the response rate was 37.2{\%} (95{\%} CI 22.8-51.6) in 43 patients, whereas responses were observed in 16 (1 complete response, 15 partial response) out of 39 evaluable patients (41{\%}, 95{\%} CI 25.6-56.5); there were 50{\%} with first-line and 33{\%} with second-line therapy, and 50 and 29{\%} of patients were considered anthracycline 'exposed' and 'resistant', respectively; responses by estrogen receptor (ER) status were given in 48{\%} (ER positive) and 25{\%} (ER negative), and by HER2 status, in 21{\%} (HER2 positive) and 52{\%} (HER2 negative). Median time to progression and median overall survival were 7.7 and 28.7 months, respectively. Toxicity was generally acceptable, with grade 3 neutropenia encountered in 15 (35{\%}) patients and grade 4 neutropenia in 1 (2{\%}) patient. Neutropenic fever occurred in 7 patients (16{\%}), usually short-lasting. Grade 3 mucositis was encountered in 2 patients (5{\%}). Conclusions: The combination of docetaxel and vinorelbine as a 3-weekly schedule is active and manageable in advanced breast cancer patients previously treated with anthracyclines.",
keywords = "Advanced breast cancer, Chemotherapy, Docetaxel, Vinorelbine",
author = "Patrizia Vici and {Di Lauro}, Luigi and Domenico Sergi and Paolo Foggi and Giuditta Viola and Marcella Mottolese and Francesco Giotta and Fattoruso, {Silvia I S} and Serena Corsetti and Diana Giannarelli and Claudio Botti and Massimo Lopez",
year = "2008",
month = "10",
doi = "10.1159/000163056",
language = "English",
volume = "75",
pages = "175--181",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3-4",

}

TY - JOUR

T1 - A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines

AU - Vici, Patrizia

AU - Di Lauro, Luigi

AU - Sergi, Domenico

AU - Foggi, Paolo

AU - Viola, Giuditta

AU - Mottolese, Marcella

AU - Giotta, Francesco

AU - Fattoruso, Silvia I S

AU - Corsetti, Serena

AU - Giannarelli, Diana

AU - Botti, Claudio

AU - Lopez, Massimo

PY - 2008/10

Y1 - 2008/10

N2 - Background: It was the aim of this study to evaluate the efficacy of docetaxel and vinorelbine combination in well-defined anthracycline-'exposed' or -'resistant' advanced breast cancer patients. Patients and Methods: A phase II trial was carried out enrolling 43 advanced breast cancer patients, all previously treated with anthracyclines, both in an adjuvant or advanced setting. Docetaxel 75 mg/m2 as 1-hour infusion and vinorelbine 25 mg/m 2 as 30-min infusion were administered on day 1, every 3 weeks. Results: According to an intent-to-treat analysis, the response rate was 37.2% (95% CI 22.8-51.6) in 43 patients, whereas responses were observed in 16 (1 complete response, 15 partial response) out of 39 evaluable patients (41%, 95% CI 25.6-56.5); there were 50% with first-line and 33% with second-line therapy, and 50 and 29% of patients were considered anthracycline 'exposed' and 'resistant', respectively; responses by estrogen receptor (ER) status were given in 48% (ER positive) and 25% (ER negative), and by HER2 status, in 21% (HER2 positive) and 52% (HER2 negative). Median time to progression and median overall survival were 7.7 and 28.7 months, respectively. Toxicity was generally acceptable, with grade 3 neutropenia encountered in 15 (35%) patients and grade 4 neutropenia in 1 (2%) patient. Neutropenic fever occurred in 7 patients (16%), usually short-lasting. Grade 3 mucositis was encountered in 2 patients (5%). Conclusions: The combination of docetaxel and vinorelbine as a 3-weekly schedule is active and manageable in advanced breast cancer patients previously treated with anthracyclines.

AB - Background: It was the aim of this study to evaluate the efficacy of docetaxel and vinorelbine combination in well-defined anthracycline-'exposed' or -'resistant' advanced breast cancer patients. Patients and Methods: A phase II trial was carried out enrolling 43 advanced breast cancer patients, all previously treated with anthracyclines, both in an adjuvant or advanced setting. Docetaxel 75 mg/m2 as 1-hour infusion and vinorelbine 25 mg/m 2 as 30-min infusion were administered on day 1, every 3 weeks. Results: According to an intent-to-treat analysis, the response rate was 37.2% (95% CI 22.8-51.6) in 43 patients, whereas responses were observed in 16 (1 complete response, 15 partial response) out of 39 evaluable patients (41%, 95% CI 25.6-56.5); there were 50% with first-line and 33% with second-line therapy, and 50 and 29% of patients were considered anthracycline 'exposed' and 'resistant', respectively; responses by estrogen receptor (ER) status were given in 48% (ER positive) and 25% (ER negative), and by HER2 status, in 21% (HER2 positive) and 52% (HER2 negative). Median time to progression and median overall survival were 7.7 and 28.7 months, respectively. Toxicity was generally acceptable, with grade 3 neutropenia encountered in 15 (35%) patients and grade 4 neutropenia in 1 (2%) patient. Neutropenic fever occurred in 7 patients (16%), usually short-lasting. Grade 3 mucositis was encountered in 2 patients (5%). Conclusions: The combination of docetaxel and vinorelbine as a 3-weekly schedule is active and manageable in advanced breast cancer patients previously treated with anthracyclines.

KW - Advanced breast cancer

KW - Chemotherapy

KW - Docetaxel

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=54749144256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54749144256&partnerID=8YFLogxK

U2 - 10.1159/000163056

DO - 10.1159/000163056

M3 - Article

C2 - 18841031

AN - SCOPUS:54749144256

VL - 75

SP - 175

EP - 181

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3-4

ER -